{"schema_version":"secwatch.filing_event.v1","accession":"0001618835-22-000211","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.457308+00:00","generated_at":"2026-06-21T00:51:55.015398+00:00","sec_items":["1.01","5.03","5.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem raises ~$1.25M net through $2.3M principal convertible notes, warrants, and preferred stock","bullets":["Raised ~$1.25M net via $2.3M principal senior secured convertible notes, warrants, and Series D Preferred Stock.","Notes convert at $0.05/share, 8% interest, mature in 3 years; warrants exercisable at $0.05 for 46.2M shares.","Series D Preferred Stock has voting rights equal to 1% of common per share, only to approve reverse stock split.","CFO Justin J. File appointed as Secretary; forbearance amended to allow up to $5M additional pari passu debt.","Net proceeds ~$1.25M after expenses; investors paid $650 per $1,000 principal."],"urls":{"canonical":"https://secwatch.observer/filing/0001618835-22-000211","json":"https://secwatch.observer/filing/0001618835-22-000211.json","markdown":"https://secwatch.observer/filing/0001618835-22-000211.md","text":"https://secwatch.observer/filing/0001618835-22-000211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000161883522000211/0001618835-22-000211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000161883522000211/evfm-20221216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:51:55.015398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9fd99e30d3","claim":"Justin J. File was appointed as Secretary at Evofem Biosciences, Inc..","evidence_excerpt":"On December 19, 2022 Company appointed Justin J. File as Secretary, effective December 16, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883522000211/0001618835-22-000211-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Secretary"}],"fact_type":"executive_change"},{"claim_id":"652af0455d9789d2dd097d146291f0399e9ccbf8","claim":"Evofem Biosciences, Inc.: 公司提交指定证书创建D系列优先股，构成公司章程修订 (effective 2022-12-16).","evidence_excerpt":"On December 16, 2022 the Company filed a certificate of designation to create the Series D Preferred Stock (the “ Certificate of Designation” ) with the Secretary of State, Division of Corporations in Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883522000211/0001618835-22-000211-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-12-16"}],"fact_type":"governance_change"},{"claim_id":"cd9149f4ed034621b318121215f1de2fd2f8aabe","claim":"Evofem Biosciences, Inc. entered into \"SPA\" with certain investors valued at $2,307,692 (effective 2022-12-20).","evidence_excerpt":"On December 20, 2022, Evofem Biosciences, Inc., a Delaware corporation (the “ Company” ), entered into a securities purchase agreement (“ SPA” ), with certain investors (the “ Investors ”) providing for the sale and issuance of senior secured convertible notes due in the aggregate original principal amount of $2,307,692 (the “ Notes” ), warrants to purchase an aggregate 46,153,847 shares of common stock (“ Warrants” ) and an aggregate 70 shares of Series D Preferred Stock (the “ Preferred Shares ”) (collectively, the “ Offering” ).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883522000211/0001618835-22-000211-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"$2,307,692"},{"label":"Effective","value":"2022-12-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}